Phesi’s SaaS predicts ‘what if’ and eases site selection costs, delays

By Maggie Lynch

- Last updated on GMT

(Image: Getty/TimeStopper)
(Image: Getty/TimeStopper)

Related tags SaaS Site selection clinical study Clinical trial AI

Phesi launches an AI-powered SaaS solution to mitigate potential costly delays through a search and select investigator function to determine trial sites for clinical studies.

The ClinSite tool launched by Phesi is a self-service, artificial intelligence (AI) powered Software as a Service (SaaS) solution, which  searches and selects investigator trial sites for biopharmaceutical companies using data collected by the clinical development analytics provider.

Phesi’s technology platform taps into data from 4.2 million physicians and 600,000 investigator sites identified from 80,000 sources and 330,000 clinical trials in 240 countries.

Jonathan Peachey, CEO of Phesi told us, “Our primary strategic goal is to partner with trial sponsors to remove barriers to conducting effective clinical trials, and to get novel therapies to patients faster​.”

“Smarter trials equal faster cures,”​ he added.

The intention behind the development of ClinSite is that it can be used directly by client teams under a SaaS, cloud-based license, “leaving Phesi to support the more difficult programs as a service, either directly or via formal alliance partners,”​ said Peachey.

According to the company, 250 clinical trials have used the solution to select investigator sites and those trials have enrolled patients 40% faster than other sites.

The solution uses an automated analytical approach and a proprietary data analytics platform, an approach, which Peachey said enables Phesi to conduct activities traditionally conducted in series and by different functional groups, simultaneously, by running ‘what if’ analyses’ in real time.

Peachey told us that the use of the service recently saved “millions of dollars by advising on the design of a gastroenterology protocol and determining the optimum number of sites requires and the best investigators.”​ The client estimated that it saved up to $5m by using the AI-based analysis.

The company expects to introduce an additional integrated module to optimize design of study protocols in 2020.

“We have seen a strong and growing demand for high quality, specialized providers in the niche we occupy, and we confidently expect dramatic further growth as the pharmaceutical industry faces increasing R&D productivity and cost pressures,”​ Peachey said.

Related news

Show more

Related products

show more

Using Define-XML to build more efficient studies

Using Define-XML to build more efficient studies

Content provided by Formedix | 14-Nov-2023 | White Paper

It is commonly thought that Define-XML is simply a dataset descriptor: a way to document what datasets look like, including the names and labels of datasets...

Why should you use clinical trial technology?

Why should you use clinical trial technology?

Content provided by Formedix | 01-Nov-2023 | White Paper

New, innovative clinical trial technology is helping to revolutionize the research landscape. COVID-19 demonstrated that clinical trials can be run much...

Overcoming rapid growth challenges with process liquid preparation

Overcoming rapid growth challenges with process liquid preparation

Content provided by Thermo Fisher Scientific - Process Liquid Preparation Services | 01-Nov-2023 | Case Study

A growing contract development manufacturing organization (CDMO) was challenged with the need to quickly expand their process liquid and buffer preparation...

Related suppliers

Follow us

Products

View more

Webinars